Faculty profile

Francois Benard

ResearcherChemistryUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.

Francois Benard

Researcher

Chemistry

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
5 publications in the last five years, latest in 2026.
Senior (last) author on 3 recent papers, a sign of leading a research group.
Principal investigator on 13 research grants (11 CIHR, 2 NSERC), most recently in 2024.
Supervised 3 trainees who won CIHR awards, most recently in 2018.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

173

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Radiopharmaceuticals Positron Emission Tomography Molecular Imaging Nuclear Medicine Radioisotopes Cancer Imaging Radiotracers Artificial Intelligence

Latest papers

Comparison of [111In]octreotide Scintigraphy and [68Ga]DOTATOC PET in Gastroenteropancreatic Neuroendocrine Tumors: Concordance of Krenning Scores and Implications for Peptide Receptor Radionuclide Therapy Eligibility.
Neuroendocrinology · 2026
A Phase I/II Study of [177Lu]Lu-HTK03170 with Personalized Dosimetry in Patients with Metastatic Castration-Resistant Prostate Cancer: Clinical Trial Protocol.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025 · senior author
5-Hydroxypyrroloindoline Affords Tryptathionine and 2,2'-bis-Indole Peptide Staples: Application to Melanotan-II.
Chemistry (Weinheim an der Bergstrasse, Germany) · 2024

All 19 publications

Latest funding

Towards state-of-the-art long axial field-of-view (LAFOV) PET/CT imaging of cancer patients
CIHR · 2025 · Co-investigator
$937,126
Precision Radiopharmaceutical Therapies with Theranostic Digital Twins
CIHR · 2024 · Principal investigator
$906,525
Next-generation GRPR-targeting radiopharmaceuticals with improved in vivo stability and minimized pancreas uptake
CIHR · 2022 · Co-investigator
$523,260

All 37 grants and awards

19 publications.

Comparison of [111In]octreotide Scintigraphy and [68Ga]DOTATOC PET in Gastroenteropancreatic Neuroendocrine Tumors: Concordance of Krenning Scores and Implications for Peptide Receptor Radionuclide Therapy Eligibility.

Fedrigo R, Harsini S, Murtha L, Solar Vasconcelos JP, Uribe C, Wilson D, Benard F, Alberts I, Martineau P, Loree JM

Neuroendocrinology2026

DOI: 10.1159/000552968 PMID: 42284283

A Phase I/II Study of [177Lu]Lu-HTK03170 with Personalized Dosimetry in Patients with Metastatic Castration-Resistant Prostate Cancer: Clinical Trial Protocol.

Harsini S, Soleimani M, Wilson D, Uribe C, Saprunoff H, Bloise I, Benard F

Journal of nuclear medicine : official publication, Society of Nuclear Medicine2025Senior author

DOI: 10.2967/jnumed.124.269064 PMID: 40306965

5-Hydroxypyrroloindoline Affords Tryptathionine and 2,2'-bis-Indole Peptide Staples: Application to Melanotan-II.

Todorovic M, Blanc A, Wang Z, Lozada J, Froelich J, Zeisler J, Zhang C, Merkens H, Benard F, Perrin DM

Chemistry (Weinheim an der Bergstrasse, Germany)2024

DOI: 10.1002/chem.202304270 PMID: 38285527

Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands.

Kwon D, Takata K, Zhang Z, Chong L, Fraser B, Zeisler J, Miyata-Takata T, Merkens H, Rousseau J, Aoki T, Kuo HT, Tan R, Zhang C, Lau J, Villa D, Uribe CF, Lin KS, Steidl C, Benard F

Clinical cancer research : an official journal of the American Association for Cancer Research2022Senior author

DOI: 10.1158/1078-0432.ccr-21-3284 PMID: 35078860

Reducing the Kidney Uptake of High Contrast CXCR4 PET Imaging Agents via Linker Modifications.

Kwon D, Zhang Z, Zeisler J, Kuo HT, Lin KS, Benard F

Pharmaceutics2022Senior author

DOI: 10.3390/pharmaceutics14071502 PMID: 35890397

Evaluation of 18F-EF5 for detection of hypoxia in localized adenocarcinoma of the prostate.

Wadsworth BJ, Decotret LR, Villamil C, Yapp D, Wilson D, Benard F, McKenzie M, Bennewith KL

Acta oncologica (Stockholm, Sweden)2021

DOI: 10.1080/0284186x.2021.1959636 PMID: 34379579

Development and biological evaluation of[18F]FMN3PA & [18F]FMN3PU for leucine-rich repeat kinase 2 (LRRK2) in vivo PET imaging.

Malik N, Kornelsen R, McCormick S, Colpo N, Merkens H, Bendre S, Benard F, Sossi V, Schirrmacher R, Schaffer P

European journal of medicinal chemistry2021

DOI: 10.1016/j.ejmech.2020.113005 PMID: 33248850

High-Contrast CXCR4-Targeted 18F-PET Imaging Using a Potent and Selective Antagonist.

Kwon D, Lozada J, Zhang Z, Zeisler J, Poon R, Zhang C, Roxin Á, Lin KS, Perrin D, Benard F

Molecular pharmaceutics2021Senior author

DOI: 10.1021/acs.molpharmaceut.0c00785 PMID: 33253591

Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation.

Wadsworth BJ, Cederberg RA, Lee CM, Firmino NS, Franks SE, Pan J, Colpo N, Lin KS, Benard F, Bennewith KL

Cancer letters2020

DOI: 10.1016/j.canlet.2020.07.015 PMID: 32763272

Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach.

Hayden AR, Tonseth P, Lee DG, Villa D, Gerrie AS, Scott DW, Freeman CL, Slack GW, Farinha P, Skinnider B, Yenson PR, Benard F, Lo A, Pickles T, Wilson D, Connors JM, Sehn LH, Savage KJ

Blood2020

DOI: 10.1182/blood.2019004296 PMID: 32603413

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2024

Subject: Prospective PhD student: Radiopharmaceuticals Dear Professor Benard, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Comparison of [111In]octreotide Scintigraphy and [68Ga]DOTATOC PET in Gastroenteropancreatic Neuroendocrine Tumors: Concordance of Krenning Scores and Implications for Peptide Receptor Radionuclide Therapy Eligibility." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Precision Radiopharmaceutical Therapies with Theranostic Digital Twins" (2024), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Francois Benard

Research

Latest papers

Latest funding

Comparison of [111In]octreotide Scintigraphy and [68Ga]DOTATOC PET in Gastroenteropancreatic Neuroendocrine Tumors: Concordance of Krenning Scores and Implications for Peptide Receptor Radionuclide Therapy Eligibility.

A Phase I/II Study of [177Lu]Lu-HTK03170 with Personalized Dosimetry in Patients with Metastatic Castration-Resistant Prostate Cancer: Clinical Trial Protocol.

5-Hydroxypyrroloindoline Affords Tryptathionine and 2,2'-bis-Indole Peptide Staples: Application to Melanotan-II.

Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands.

Reducing the Kidney Uptake of High Contrast CXCR4 PET Imaging Agents via Linker Modifications.

Evaluation of 18F-EF5 for detection of hypoxia in localized adenocarcinoma of the prostate.

Development and biological evaluation of[18F]FMN3PA & [18F]FMN3PU for leucine-rich repeat kinase 2 (LRRK2) in&#xa0;vivo PET imaging.

High-Contrast CXCR4-Targeted 18F-PET Imaging Using a Potent and Selective Antagonist.

Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation.

Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach.

Frequent collaborators

Kuo-Shyan Lin

Paul Schaffer

Carlos Uribe

David Perrin

Michael Mckenzie

Frank Wuest

Heather Ross

Alan Nichol

Lisa Mielniczuk

Vesna Sossi

Lloyd Duchesne

Heather Ross

John F Valliant

Andre Lamy

Ernest Leo Fallen

Christian Steidl

Paul Hendry

Development and biological evaluation of[18F]FMN3PA & [18F]FMN3PU for leucine-rich repeat kinase 2 (LRRK2) in vivo PET imaging.